Concepedia

Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease

Kumpal Madrasi, Raibatak Das, Hafiz Mohmmad‐Abdul, Lin Lin, Bradley T. Hyman, Douglas A. Lauffenburger, Mark W. Albers, Robert A. Rissman, John M. Burke, Joshua F. Apgar,

Alzheimer s & Dementia · 2021 · 42 citations · 32 references

DOIFull text

Open access

Abstract

A QSP model can provide novel insights to clinical results. Our model explains the results of clinical trials and provides guidance for future therapeutic development.

References

32

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3K citations

, , +7

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Kwasi G. Mawuenyega, Wendy Sigurdson, Vitaliy Ovod et al. · Science · 2010 · 2K citations · Full text

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Frédérique Bard, Catherine Cannon, Robin Barbour et al. · Nature Medicine · 2000 · 2K citations · Full text

, , +13

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

Jeffrey L. Cummings, Travis Morstorf, Kate Zhong · Alzheimer s Research & Therapy · 2014 · 1.7K citations · Full text